This press release shares data gathered by DelveInsight—a healthcare-focused market research and consulting firm. This article is super exciting and hopeful, as it shows some promising IBD therapies in the pipeline, from pills to subcutaneous injections to IV biologics.

One of the therapies listed under “promising ulcerative colitis therapies” is oral vancomycin! I believe there’s hope that one day, oral vancomycin may become a widely-accepted therapy for IBD/PSC.